Mycophenolate or tacrolimus compared with cyclophosphamide for the management of lupus nephritis: Systematic review and meta-analysis;Micofenolato o tacrolimus comparado con ciclofosfamida en el tratamiento de nefritis lúpica: Revisión sistemática y metaanálisis

Revista Colombiana de Reumatologia

Volumn 21, Issue 4, 2014, Pages 213-225

  Páez Ardila, Hugo Alberto ^a   Suárez, Libardo Enrique Lobato ^a   Rodríguez, Viviana Alejandra ^b   Quintana, Gerardo L ^c,d,e  

^a HOSPITAL UNIVERSITARIO MAYOR MÉDERI   (Colombia)

^b UNIVERSIDAD EL BOSQUE   (Colombia)

^c UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^d UNIVERSIDAD DE LOS ANDES   (Colombia)

^e Fundacion Santafe de Bogota   (Colombia)

Author keywords

Cyclophosphamide; FK506; Glomerulonephritis; Lupus nephritis; Mycophenolate mofetil; Mycophenolic acid; Nephritis; Systemic lupus erythematosus; Tacrolimus

Indexed keywords

CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID; TACROLIMUS;

CONTROLLED CLINICAL TRIAL (TOPIC); DEATH; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; META ANALYSIS; REMISSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84955196285     PISSN: 01218123     EISSN: 20279000     Source Type: Journal    
DOI: 10.1016/j.rcreu.2014.10.003     Document Type: Short Survey

References (28)

1. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al, European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003; 82: 299-308.
2. Cameron JS Lupus nephritis. J Am Soc Nephrol. 1999; 10: 413-24.
3. Kimberly RP Immune complexes in the rheumatic diseases. Rheum Dis Clin North Am. 1987; 13: 583-96.
4. Pinto LF, Guerra L, González JR. Lupus eritematoso sistémico: análisis del comportamiento clínico en una población de Medellín. Rev Colomb Reumatol. 2005; 4: 170-3.
5. Weening JJ, Dagati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004; 15: 241-50.
6. Flanc RS, Roberts MA, Strippoli GF, Chadban SJ, Kerr PG, Atkins RC. Treatment of diffuse proliferative lupus nephritis: A meta-analysis of randomized controlled trials. Am J Kidney Dis. 2004; 43: 197-220.
7. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000; 343: 1156-62.
8. Chan TM, Tse KC, Tang CS, Mok MY, Li FK, Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005; 16: 1076-84.
9. Szeto CC, Kwan BC, Lai FM, Tam LS, Li EK, Chow KM, et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatol. 2008; 47: 1678-81.
10. Lee T, Oh KH, Joo KW, Kim YS, Ahn C, Han JS, et al. Tacrolimus is an alternative therapeutic option for the treatment of refractory lupus nephritis. Lupus. 2010; 19: 974-80.
11. Jiménez S, Cervera R, Font J, Ingelmo M. The epidemiology of systemic lupus erythematosus. Clin Rev Allergy Immunol. 2003; 25: 3-12.
12. Seligman VA, Lum RF, Olson JL, Li H, Criswell LA. Demographic differences in the development of lupus nephritis: A retrospective analysis. Am J Med. 2002; 112: 726-9.
13. Review Manager (RevMan) [computerprogram]. Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177-88.
15. Epidat 3.0: Análisis epidemiológico de datos tabulados. [Internet]. Xunta de Galicia, Consellería de Sanidade [acceso 23 Nov 2005]. Disponible en: http://dxsp.sergas.es/default.asp
16. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005; 353: 2219-28.
17. Mulic-Bacic S, Antic D, Krizic M, Hajdarovic A, Mulic E. Mycophenolate mofetil or intravenous cyclophosphamide in treatment of lupus nephritis. Ann Rheum Dis. 2008; 67 Suppl II: 349.
18. Appel G, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al, Aspreva Lupus Management Study Group. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009; 20: 1103-12.
19. Mak A, Cheak AA, Tan JY, Su HC, Ho RC, Lau CS. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: A meta-analysis and meta-regression. Rheumatol. 2009; 48: 944-52.
20. Mohan S, Radhakrishnan J. Geographical variation in the response of lupus nephritis to mycophenolate mofetil induction therapy. Clin Nephrol. 2011; 75: 233-41.
21. Xin J, Gu Y Tacrolimus versus intravenous cyclophosphamide as the induction therapy for severe lupus nephritis: A meta-analysis of randomized controlled trials. Nephrol Dial Transplantation Plus. 2010; Suppl 3: S383.
22. Wang J, Hu W, Xie H, Zhang H, Chen H, Zeng C, et al. Induction therapies for class iv lupus nephritis with non-inflammatory necrotizing vasculopathy: Mycophenolate mofetil or intravenous cyclophosphamide. Lupus. 2007; 16: 707-12.
23. Ong LM, Hooi LS, Lim TO, Goh BL, Ahmad G, Ghazalli R, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton). 2005; 10: 504-10.
24. El-Shafey E, Abdou SH, Shareef M. Is Mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in Egyptian patients? Clin Exp Nephrol. 2010; 14: 214-21.
25. Touma Z, Gladman DD, Urowitz MB, Beyene J, Uleryk EM, Shah PS. Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J Rheumatol. 2011; 38: 69-78.
26. Chen W, Tang X, Liu Q, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. Am J Kidney Dis. 2011; 57: 235.
27. Hong R, Haijin Y, Xianglin W, Cuilan H, Nan C. A preliminary study of Tacrolimus versus cyclophosphamide in patients with diffuse proliferative lupus nephritis. Oxf Journ. 2007: SaP131.
28. Li X, Ren H, Zhang Q, Zhang W, Wu X, Xu X, et al. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant. 2012; 27: 1467-72.